作者:Douglas W. Thomson、Daniel Poeckel、Nico Zinn、Christina Rau、Katrin Strohmer、Anne J. Wagner、Alan P. Graves、Jessica Perrin、Marcus Bantscheff、Birgit Duempelfeld、Viera Kasparcova、Joshi M. Ramanjulu、G. Scott Pesiridis、Marcel Muelbaier、Giovanna Bergamini
DOI:10.1021/acsmedchemlett.9b00027
日期:2019.5.9
Herein, we report the discovery and characterization of a novel potent and highly selective TBK1 inhibitor, GSK8612. In cellular assays, this small molecule inhibited toll-like receptor (TLR)3-induced interferon regulatory factor (IRF)3 phosphorylation in Ramos cells and type I interferon (IFN) secretion in primary human mononuclear cells. In THP1 cells, GSK8612 was able to inhibit secretion of interferon
丝氨酸/苏氨酸蛋白激酶TBK1(Tank结合激酶1)是IkB激酶(IKK)家族的非典型成员。该激酶调节先天免疫,肿瘤发生,能量稳态,自噬和神经炎症中的信号传导途径。在本文中,我们报告了新型有效且高度选择性的TBK1抑制剂GSK8612的发现和表征。在细胞分析中,该小分子抑制了Ramos细胞中Toll样受体(TLR)3诱导的干扰素调节因子(IRF)3磷酸化,并抑制了人类原代单核细胞中的I型干扰素(IFN)分泌。在THP1细胞中,GSK8612能够响应dsDNA和cGAMP(STING的天然配体)而抑制干扰素β(IFNβ)的分泌。